<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466412</url>
  </required_header>
  <id_info>
    <org_study_id>P2M-PK-04-JP</org_study_id>
    <secondary_id>P2M-PK-04-JP</secondary_id>
    <nct_id>NCT02466412</nct_id>
  </id_info>
  <brief_title>Nicotine Pharmacokinetic Profile of the CHTP 1.1 M</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M) Following Single Use in Smoking, Healthy Subjects Compared to Menthol Conventional Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile
      of nicotine (rate and amount of nicotine absorbed) after single use of the Carbon Heated
      Tobacco Product 1.1 Menthol (CHTP 1.1 M), a potential Modified Risk Tobacco Product, compared
      to menthol cigarettes (mCC) in healthy smokers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Nicotine Following Single Use of CHTP 1.1 M and mCC</measure>
    <time_frame>Day 3: blood taken 15 minutes prior to T0, 2, 4, 6, 8, 10, 15, 30, 45 minutes, 1, 2, 4, 6, 9, 12, and 24 hours after T0.</time_frame>
    <description>T0 = start of single product use.
Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares (LS) means are provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of CHTP 1.1 M and mCC</measure>
    <time_frame>Day 3: blood taken 15 minutes prior to T0, 2, 4, 6, 8, 10, 15, 30, 45 minutes, 1, 2, 4, 6, 9, 12, and 24 hours after T0.</time_frame>
    <description>T0 = start of single product use.
Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares means are provided.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>CHTP 1.1 M then mCC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day -1 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of CHTP 1.1 M)
Day 2 = Wash-out
Day 3 = 2nd intervention (single product use of mCC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mCC then CHTP 1.1 M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day -1 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mCC)
Day 2 = Wash-out
Day 3 = 2nd intervention (single product use of CHTP 1.1 M).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHTP 1.1 M</intervention_name>
    <description>Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)</description>
    <arm_group_label>CHTP 1.1 M then mCC</arm_group_label>
    <arm_group_label>mCC then CHTP 1.1 M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mCC</intervention_name>
    <description>Single use of subject's own menthol conventional cigarette (mCC)</description>
    <arm_group_label>CHTP 1.1 M then mCC</arm_group_label>
    <arm_group_label>mCC then CHTP 1.1 M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is Japanese.

          -  Subject is at a minimum 23 years of age.

          -  Smoking, healthy subject as judged by the Investigator.

          -  Subject has smoked for at least the last 3 years

          -  Subject smoked at least 10 commercially available mCCs per day over the last 4 weeks.

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason).

          -  Subject has received medication within 14 days or within 5 half-lives of a drug
             (whichever is longer) which has an impact on CYP2A6 activity.

          -  Female subject is pregnant or breast feeding.

          -  Female subject does not agree to use an acceptable method of effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fumimasa Nobuoka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ageo Medical Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ageo Medical Clinic</name>
      <address>
        <city>Saitama</city>
        <zip>362-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <results_first_submitted>February 17, 2017</results_first_submitted>
  <results_first_submitted_qc>February 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2017</results_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>nicotine absorption</keyword>
  <keyword>potential modified risk tobacco product</keyword>
  <keyword>cigarette</keyword>
  <keyword>Carbon Heated Tobacco Product</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study initiated (first subject screened): 08 May 2015
On Day -3 (admission), after all inclusion/exclusion criteria were checked, all eligible subjects were enrolled and tried CHTP 1.1 M.
From enrollment, they were asked to remain abstinent from smoking for at least 24 hours before being randomized on Day 1 into 1 of the 2 sequences.</recruitment_details>
      <pre_assignment_details>Number of subjects enrolled = 56, but only 48 were randomized as described below:
Sequence &quot;CHTP 1.1 M then mCC&quot;: 24 subjects
Sequence &quot;mCC then CHTP 1.1 M&quot;: 24 subjects
Number of subjects enrolled but NOT randomized = 8</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CHTP 1.1 M Then mCC</title>
          <description>Each subject will follow the below study design:
Day -1 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of CHTP 1.1 M)
Day 2 = Wash-out
Day 3 = 2nd intervention (single product use of mCC).</description>
        </group>
        <group group_id="P2">
          <title>mCC Then CHTP 1.1 M</title>
          <description>Each subject will follow the below study design:
Day -1 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mCC)
Day 2 = Wash-out
Day 3 = 2nd intervention (single product use of CHTP 1.1 M).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Washout Period of 1 Day (Day -1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Intervention (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period of 1 Day (Day 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (Day 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The overall PK population consisted of 47 subjects.
1 subject was excluded from the PK population (sequence &quot;CHTP 1.1 M then mCC&quot; ) due to all plasma nicotine concentration measurements being below the quantification limit for both CHTP 1.1 M and mCC.</population>
      <group_list>
        <group group_id="B1">
          <title>CHTP 1.1 M Then mCC</title>
          <description>Each subject will follow the below study design:
Day -1 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of CHTP 1.1 M)
Day 2 = Wash-out
Day 3 = 2nd intervention (single product use of mCC).</description>
        </group>
        <group group_id="B2">
          <title>mCC Then CHTP 1.1 M</title>
          <description>Each subject will follow the below study design:
Day -1 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mCC)
Day 2 = Wash-out
Day 3 = 2nd intervention (single product use of CHTP 1.1 M).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="10.03"/>
                    <measurement group_id="B2" value="40.7" spread="11.48"/>
                    <measurement group_id="B3" value="42.6" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Organization for Standardization (ISO) nicotine Yield</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>≤ 0.6 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 0.6 to ≤ 1 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Nicotine Following Single Use of CHTP 1.1 M and mCC</title>
        <description>T0 = start of single product use.
Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares (LS) means are provided.</description>
        <time_frame>Day 3: blood taken 15 minutes prior to T0, 2, 4, 6, 8, 10, 15, 30, 45 minutes, 1, 2, 4, 6, 9, 12, and 24 hours after T0.</time_frame>
        <population>The PK population consisted of 47 subjects.
1 subject was excluded from the PK population (sequence &quot;CHTP 1.1 M then mCC&quot;) due to all plasma nicotine concentration measurements being below the quantification limit for both CHTP 1.1 M and mCC.</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.1 M</title>
            <description>The geometric least square mean presented below takes into consideration the data of all the subjects included in the PK population after single use of CHTP 1.1 M.</description>
          </group>
          <group group_id="O2">
            <title>Menthol Cigarette (mCC)</title>
            <description>The geometric least square mean presented below takes into consideration the data of all the subjects included in the PK population after single use of mCC.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Nicotine Following Single Use of CHTP 1.1 M and mCC</title>
          <description>T0 = start of single product use.
Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares (LS) means are provided.</description>
          <population>The PK population consisted of 47 subjects.
1 subject was excluded from the PK population (sequence &quot;CHTP 1.1 M then mCC&quot;) due to all plasma nicotine concentration measurements being below the quantification limit for both CHTP 1.1 M and mCC.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2950" lower_limit="5.2610" upper_limit="7.5322"/>
                    <measurement group_id="O2" value="9.8463" lower_limit="8.2290" upper_limit="11.7815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The objective of this study was to determine the point estimate and precision of the CHTP 1.1 M:mCC ratio for Cmax. Therefore, there was no statistical hypothesis to be tested for this objective.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>63.9326</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.6045</ci_lower_limit>
            <ci_upper_limit>82.3991</ci_upper_limit>
            <estimate_desc>Geometric LS mean ratio (CHTP 1.1 M:mCC).
Expressed as %</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of CHTP 1.1 M and mCC</title>
        <description>T0 = start of single product use.
Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares means are provided.</description>
        <time_frame>Day 3: blood taken 15 minutes prior to T0, 2, 4, 6, 8, 10, 15, 30, 45 minutes, 1, 2, 4, 6, 9, 12, and 24 hours after T0.</time_frame>
        <population>The PK population consisted of 47 subjects.
1 subject was excluded from the PK population (sequence &quot;CHTP 1.1 M then mCC&quot;) due to all plasma nicotine concentration measurements being below the quantification limit for both CHTP 1.1 M and mCC.</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.1 M</title>
            <description>The geometric least square mean presented below takes into consideration the data of all the subjects included in the PK population after single use of CHTP 1.1 M.</description>
          </group>
          <group group_id="O2">
            <title>Menthol Cigarette (mCC)</title>
            <description>The geometric least square mean presented below takes into consideration the data of all the subjects included in the PK population after single use of mCC.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of CHTP 1.1 M and mCC</title>
          <description>T0 = start of single product use.
Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares means are provided.</description>
          <population>The PK population consisted of 47 subjects.
1 subject was excluded from the PK population (sequence &quot;CHTP 1.1 M then mCC&quot;) due to all plasma nicotine concentration measurements being below the quantification limit for both CHTP 1.1 M and mCC.</population>
          <units>h*ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5311" lower_limit="6.9550" upper_limit="10.4642"/>
                    <measurement group_id="O2" value="14.2172" lower_limit="11.5908" upper_limit="17.4388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The objective of this study was to determine the point estimate and precision of the CHTP 1.1 M:mCC ratio for AUC(0-last). Therefore, there was no statistical hypothesis to be tested for this objective.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>60.0052</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.9517</ci_lower_limit>
            <ci_upper_limit>80.0997</ci_upper_limit>
            <estimate_desc>Geometric LS mean ratio (CHTP 1.1 M:mCC).
Expressed as %</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the informed consent form (ICF) signature until the end of the safety follow-up period (7 days after discharge of the subject).</time_frame>
      <desc>The safety was assessed in the safety population, consisting of 56 subjects: 48 randomized subjects (24 subjects in the &quot;CHTP 1.1 M then mCC&quot; sequence, 24 subjects in the &quot;mCC then CHTP 1.1 M&quot; sequence), and 8 non-randomized subjects who were exposed to CHTP 1.1 M from the product test on Admission.</desc>
      <group_list>
        <group group_id="E1">
          <title>CHTP 1.1 M Then mCC</title>
          <description>Each subject will follow the below study design:
Day -1 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of CHTP 1.1 M)
Day 2 = Wash-out
Day 3 = 2nd intervention (single product use of mCC).</description>
        </group>
        <group group_id="E2">
          <title>mCC Then CHTP 1.1 M</title>
          <description>Each subject will follow the below study design:
Day -1 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mCC)
Day 2 = Wash-out
Day 3 = 2nd intervention (single product use of CHTP 1.1 M).</description>
        </group>
        <group group_id="E3">
          <title>Enrolled But Not Randomized</title>
          <description>Subjects who tried the CHTP 1.1 M at Admission but were not randomized in 1 of the 2 sequences as they were back-up subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.
The Intellectual Property rights and research results from the present study belong to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steffen Fredersdorf</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 (58) 242 2182</phone>
      <email>Steffen.Fredersdorf@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

